Barclays analyst Carter Gould lowered the firm’s price target on Gossamer Bio to $1.50 from $2 and keeps an Equal Weight rating on the shares post the Q4 results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GOSS:
- Gossamer Bio options imply 16.5% move in share price post-earnings
- Gossamer Bio reports Q4 EPS (59c), consensus (62c)
- Gossamer Bio options imply 6.3% move in share price post-earnings
- Gossamer Bio options imply 36.4% move in share price post-earnings
- Gossamer Bio downgraded to Market Perform from Outperform at Raymond James